Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients

Thrombosis Research

Volumn 125, Issue 5, 2010, Pages

  Althoff, Till F ^a   Fischer, Matthias ^a   Langer, Elisabeth ^a   Ziemer, Sabine ^a   Baumann, Gert ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute coronary syndrome; Aspirin resistance; Clopidogrel resistance; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; FIBRINOGEN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; ELECTIVE SURGERY; FEMALE; HEART INFARCTION; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; REACTION TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

CORONARY VESSELS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PLATELET AGGREGATION; STENTS; TREATMENT OUTCOME;

EID: 77951667161     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.01.003     Document Type: Article

References (48)

1. Dupont A.G., Gabriel D.A., and Cohen M.G. Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thromb Res 124 (2009) 6-13
2. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
3. Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R., et al. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
4. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE). Investigators Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
5. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., et al. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
6. Bhatt D.L., Bertrand M.E., Berger P.B., L'Allier P.L., Moussa I., Moses J.W., et al. Meta-analysis of randomized and registry comparison of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 39 (2002) 9-14
7. Silber S., Albertsson P., Avilés F.F., Camici P.G., Colombo A., Hamm C., et al. Guidelines for percutaneous coronary interventions. Eur Heart J 26 (2005) 804-847
8. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand J.P., Hamm C.W., Ardissino D., Boersma E., Budaj A., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28 (2007) 1598-1660
9. Van de Werf F., Bax J., Betriu A., Blomstrom-Lundqvist C., Crea F., Falk V., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29 (2008) 2909-2945
10. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., and Topol E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
11. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
12. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
13. Shantsila E., Watson T., and Lip G.Y. Aspirin resistance: what, why and when?. Thromb Res 119 (2007) 551-554
14. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
15. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
16. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
17. Marcucci R., Gori A.M., Paniccia R., Giusti B., Valente S., Giglioli C., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119 (2009) 237-242
18. Krasopoulos G., Brister S.J., Beattie W.S., and Buchanan M.R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336 (2008) 195-198
19. Hochholzer W., Trenk D., Bestehorn H.P., Fischer B., Valina C.M., Ferenc M., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
20. Sibbing D., Braun S., Morath T., Mehilli J., Vogt W., Schömig A., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53 (2009) 849-856
21. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., and Huisman M.V. Association of laboratory-defined aspirin resistance with a high risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167 (2007) 1593-1599
22. Samara W.M., Bliden K.P., Tantry U.S., and Gurbel P.A. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 115 (2005) 89-94
23. Ault K.A., Cannon C.P., Mitchell J., McCahan J., Tracy R.P., Novotny W.F., et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 33 (1999) 634-639
24. Gurbel P.A., Bliden K.P., Hayes K.M., and Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2 (2004) 535-545
25. Geisler T., Kapp M., Göhring-Frischholz K., Daub K., Dösch C., Bigalke B., et al. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 94 (2008) 685-687
26. Kastrati A., Mehilli J., Neumann F.J., Dotzer F., ten Berg J., Bollwein H., et al. Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
27. De Luca G., Ucci G., Cassetti E., and Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis of randomized trials. J Am Coll Cardiol 53 (2009) 1668-1673
28. Reganon E., Vila V., Martinez-Sales V., Vaya A., and Aznar J. Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction. Haematologica 87 (2002) 740-745
29. Merlini P.A., Bauer K.A., Oltrona L., Ardissino D., Cattaneo M., Belli C., et al. Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial-Infarction. Circulation 90 (1994) 61-68
30. Mulvihill N.T., Foley J.B., Murphy R., Crean P., and Walsh M. Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 36 (2000) 1210-1216
31. Biasucci L.M., Liuzzo G., Grillo R.L., Caligiuri G., Rebuzzi A.G., Buffon A., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99 (1999) 855-860
32. Lordkipanidzé M., Pharand C., Palisaitis D.A., Schampaert E., and Diodati J.G. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. Thromb Res 124 (2009) 546-553
33. Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., and Michelson A.D. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50 (2007 Nov 6) 1822-1834
34. Tóth O., Calatzis A., Penz S., Losonczy H., and Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 96 (2006) 781-788
35. Mueller T., Dieplinger B., Poelz W., Calatzis A., and Haltmayer M. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer-comparison with two flow cytometric methods. Thromb Res 121 (2007) 249-258
36. Gawaz M., Ott I., and Neumann F.J. Surface expression of platelet membrane glycoproteins following coronary stenting: effect on subacute stent thrombosis?. Circulation 90 (1994) I-552
37. Fox S.C., Behan M.W., and Heptinstall S. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 35 (2004) 39-46
38. Mehta S.R., Bassand J.P., Chrolavicius S., Diaz R., Fox K.A., Granger C.B., et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 156 (2008) 1080-1088
39. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
40. Manoukian S.V., Feit F., Mehran R., Voeltz M.D., Ebrahimi R., Hamon M., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49 (2007) 1362-1368
41. Feit F., Voeltz M.D., Attubato M.J., Lincoff A.M., Chew D.P., Bittl J.A., et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol 100 (2007) 1364-1369
42. Ndrepepa G., Berger P.B., Mehilli J., Seyfarth M., Neumann F.J., Schömig A., et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51 (2008) 690-697
43. Budaj A., Eikelboom J.W., Mehta S.R., Afzal R., Chrolavicius S., Bassand J.P., et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 30 (2009) 655-661
44. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 361 (2009) 1108-1111
45. Gurbel P.A., Bliden K.P., Kreutz R.P., Dichiara J., Antonino M.J., and Tantry U.S. The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. Platelets 20 (2009) 97-104
46. Ang L., Palakodeti V., Khalid A., Tsimikas S., Idrees Z., Tran P., et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 52 (2008) 1052-1059
47. Kuliczkowski W., Witkowski A., Polonski L., Watala C., Filipiak K., Budaj A., et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 30 4 (2009) 426-435
48. Lordkipanidze M., Pharand C., Schampaert E., Turgeon J., Palisaitis D.A., and Diodati J.G. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28 (2007) 1702-1708